Archblock Announces Rebranding of Stablecoin Portfolio
12.9.2023 18:18:00 EEST | Business Wire | Press release
Archblock, enabling open access to financial opportunities and global trade, is thrilled to announce the rebranding of its portfolio of stablecoins, previously known as TrueCoin. The Archblock Stablecoins portfolio features fiat-backed stablecoins pegged to the GBP, CAD and AUD. The company plans to introduce an HKD stablecoin after the licensing requirements are established.
In addition to its portfolio of stablecoins, Archblock Stablecoins offers the technical and operational foundation to build white-label stablecoins for others. Archblock launched the first institutional-grade fiat-backed stablecoin, TrueUSD (“TUSD”), in 2018 as a proof of concept in asset-backed token development. TUSD has since been sold to Techteryx, who continues to operate the stablecoin. As of June 30, 2023, the market capitalization of TUSD exceeded $3.0B. With experience in building scalable white-label stablecoins, Archblock is excited to continue developing and implementing stablecoin platforms customized to meet the needs of its partners. Archblock Stablecoins services include bank-grade customer onboarding with audited KYC/AML, smart contract development and maintenance, bank integration, exchange listings for liquidity, white-labeled user-facing application for minting and redeeming, and industry-leading security.
Designed to overcome the limitations of traditional banking systems, Archblock is committed to leveraging the global potential of blockchain technology. Initially created as a secure and trusted on-and-off ramp for on-chain investors, Archblock's stablecoin offering has evolved. It now serves as the foundation for next-generation financial services, taking advantage of blockchain's transparency, immutability and efficient settlement processes. Stablecoins enable 24/7 transactions and reduce the friction and costs associated with traditional banking, and promote financial inclusion, allowing users to transact easily globally.
Alex de Lorraine, Chief Executive Officer of Archblock, stated, “Our stablecoin management system is engineered with a focus on the customer experience, catering to businesses, institutional users and retail users alike. Our stablecoins are built with transparency and regulatory compliance at the forefront. We ensure transparency and equal access to information by partnering with third parties for real-time independent attestations, external audits, and proof-of-reserves. Our aim is to use web3 enabled finance systems to democratize financial solutions that have historically been available only to those with access to traditional banking institutions. Whether investing in digital assets on-chain or transacting with businesses that accept digital currencies, our stablecoins offer a more efficient and cost-effective option.”
The Archblock Stablecoins portfolio is accessible on 12 blockchains and over 90 exchanges. It is available to all users who meet the KYC/KYB requirements.
About Archblock Stablecoins
Archblock is expanding access to financial opportunities and global trade with its Archblock Stablecoins portfolio and Archblock Marketplace. Archblock Stablecoins offers the technical and operational foundation to build white-label stablecoins for others, and operates a portfolio of fiat-backed stablecoins. For more information about Archblock Stablecoins, please contact Archblock at support@archblock.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912852354/en/
Contact information
Media Contact:
Kelly Ferraro, River North Communications
1-646-275-7040
kelly@rivernorthagency.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom